Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.895 USD | -0.56% | +1.64% | -31.15% |
26/03 | Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
19/03 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
Sales 2024 * | - | Sales 2025 * | 5M 417M | Capitalization | 6.53M 544M |
---|---|---|---|---|---|
Net income 2024 * | -18M -1.5B | Net income 2025 * | -13M -1.08B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.31 x |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
-0.88
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.94% |
1 day | -0.56% | ||
1 week | +1.64% | ||
Current month | -10.50% | ||
1 month | -10.50% | ||
3 months | -0.28% | ||
6 months | -50.28% | ||
Current year | -31.15% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Tucker
CEO | Chief Executive Officer | 55 | 16/21/16 |
Kevin Coveney
DFI | Director of Finance/CFO | 60 | 13/23/13 |
Jillian Hagel
CTO | Chief Tech/Sci/R&D Officer | 45 | 16/21/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Webb
CHM | Chairman | 66 | 13/22/13 |
Joseph Tucker
CEO | Chief Executive Officer | 55 | 16/21/16 |
Frank Pasqualone
BRD | Director/Board Member | 68 | 13/22/13 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.895 | -0.56% | 58,269 |
25/24/25 | 0.9 | -3.64% | 88,601 |
24/24/24 | 0.934 | +4.08% | 184,679 |
23/24/23 | 0.8974 | +4.23% | 71,434 |
22/24/22 | 0.861 | -2.23% | 110,502 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.15% | 6.53M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ENVB Stock